Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2012 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Long-Term Deferred Tax came in at $55.1 million in Q1 2026, up 14.29% YoY from $48.2 million in Q1 2025, and up 4.44% on a QoQ basis from $52.8 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2012 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 11 years of Long-Term Deferred Tax data on file, last reported at $55.1 million in Q1 2026.
- Quarterly Long-Term Deferred Tax rose 14.29% year-over-year to $55.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.1 million (up 14.29% YoY) and the FY2025 annual result came in at $52.8 million, up 14.76% from the prior year.
- Long-Term Deferred Tax advanced to $55.1 million in Q1 2026, from $52.8 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $55.1 million in Q1 2026 to a low of $18.7 million in Q4 2022.
- A 5-year average of $36.9 million and a median of $38.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2022 — Long-Term Deferred Tax plunged 30.33% — and 2023, when it jumped 95.05%.
- Tracing CPRX's Long-Term Deferred Tax over 5 years: stood at $18.7 million in 2022, then jumped by 95.05% to $36.5 million in 2023, then gained by 25.83% to $46.0 million in 2024, then advanced by 14.76% to $52.8 million in 2025, then rose by 4.44% to $55.1 million in 2026.
- The last three Long-Term Deferred Tax figures came in at $55.1 million (Q1 2026), $52.8 million (Q4 2025), and $48.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.11 Mn |
| Dec 31, 2025 | 52.77 Mn |
| Sep 30, 2025 | 48.26 Mn |
| Jun 30, 2025 | 50.70 Mn |
| Mar 31, 2025 | 48.22 Mn |
| Dec 31, 2024 | 45.98 Mn |
| Sep 30, 2024 | 48.47 Mn |
| Jun 30, 2024 | 39.89 Mn |
| Mar 31, 2024 | 38.28 Mn |
| Dec 31, 2023 | 36.54 Mn |
| Sep 30, 2023 | 37.43 Mn |
| Jun 30, 2023 | 23.49 Mn |
| Mar 31, 2023 | 20.24 Mn |
| Dec 31, 2022 | 18.74 Mn |
| Sep 30, 2022 | 20.03 Mn |
| Jun 30, 2022 | 20.93 Mn |
| Mar 31, 2022 | 21.89 Mn |
| Dec 31, 2021 | 23.70 Mn |
| Sep 30, 2021 | 26.40 Mn |
| Jun 30, 2021 | 28.70 Mn |